Option Care Health, Inc. Common Stock OPCH

Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.

OPCH hizo una agrupación de acciones (split inverso) de 1:4 el 3 de febrero de 2020: cada 4 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 30 sept

  BTSG Deploys AI Across Operations: Will It Improve Margins?

  BrightSpring Health Services is leveraging AI and automation across hiring, intake, documentation, and patient care to improve productivity. The company reported 44% year-over-year adjusted EBITDA growth with margin expansion to 5.3%, with further benefits expected in late 2026 and early 2027. Peers Option Care Health and Addus HomeCare are similarly implementing AI-driven initiatives to enhance efficiency and reduce operational complexity.

  

• Zacks Investment Research 30 sept

  Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

  Zacks highlights two healthcare stocks as strong value investment opportunities: Fresenius SE & Co. (FSNUY) with a Zacks Rank #2 and Value grade A, trading at a P/E of 13.26 below its industry average of 18.36; and Option Care Health (OPCH) also with Rank #2 and Value grade A, trading at a forward P/E of 15.09. Both stocks are presented as undervalued based on multiple valuation metrics including P/S, P/CF, and P/B ratios.

  

• Zacks Investment Research 16 sept

  Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

  Quest Diagnostics (DGX) has reached a new 52-week high of $248.65, gaining 42.4% year-to-date with a strong track record of beating earnings estimates. The stock carries a Zacks Rank #2 (Buy) with a B VGM Score, though it trades at a premium valuation of 22.2X current fiscal year EPS versus the industry average of 20.4X. The Medical - Outpatient and Home Healthcare industry is in the top 18% of all industries, providing positive tailwinds for the sector.

  

• Zacks Investment Research 4 sept

  Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?

  BrightSpring Health Services (BTSG) reported acute infusion volume growth exceeding 20% year-over-year in Q2, roughly 7-8x the overall infusion market growth rate. The company plans to expand into 12-15 additional states over five years to capitalize on a fragmented $20 billion addressable market. Management is investing in infrastructure, AI-enabled intake, and analytics to support expansion, with the stock up 64% year-to-date and rated as a Zacks Rank #1 Strong Buy.

  

• Zacks Investment Research 31 ago

  Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare

  The Outpatient & Home Healthcare industry is experiencing rapid growth driven by digital transformation, an aging population, and cost-effectiveness advantages. The industry has a Zacks Industry Rank #52 (top 21%) with a forward P/E of 19.1X. Four key stocks are highlighted: LifeStance Health (Rank #2) with 19.7% revenue growth, Option Care Health (Rank #2) with 1.9% revenue growth, Aveanna Healthcare (Rank #2) with 10.6% revenue growth, and DaVita (Rank #3) with 4.7% revenue growth.